GDRX on Nasdaq

GoodRx

Logo: GoodRx, Inc., Public domain, via Wikimedia Commons5

American healthcare company

GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

$796.9MRevenue, fiscal 20256
$30.4MNet income, fiscal 20256
Sep 2011Founded1

Compare with Upwork, LiveRamp or NERDWALLET, INC., or pick any stock.

  • TickerGDRX on Nasdaq1
  • Industryhealth care industry1
  • HeadquartersSanta Monica1
  • Websitewww.goodrx.com
  • Legal formDelaware corporation, privately held company1
  • Incorporated inDE7
  • Business address2701 Olympic Boulevard, Santa Monica, Ca 904047
  • Filer categoryAccelerated filer7
  • LEI25490061CWK7F0OTY2604
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 50364584

GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

11.0%Operating margin6
3.8%Net margin6
0.6%Revenue growth, 20256
4.9%Return on equity6
0.78×Debt to equity6
$164.4MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Prescription Transactions Revenue brought in 68% of the revenue GoodRx broke down this way in fiscal 2025.

  1. Prescription Transactions Revenue$544.0M668%down 6% from 2024
  2. Pharma Direct Revenue$151.4M619%up 41% from 2024
  3. Subscription Revenue$83.8M611%down 3% from 2024
  4. Other Revenue$17.7M62%down 16% from 2024
Products and services by year
Products and services202320242025
Prescription Transactions Revenue$550.7M$577.5M$544.0M
Pharma Direct Revenue$85.1M$107.2M$151.4M
Subscription Revenue$94.4M$86.5M$83.8M
Other Revenue$20.1M$21.0M$17.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development15¢$121.0M
  • Other costs78¢$619.3M
  • Income tax3¢$26.1M
  • Profit4¢$30.4M

Out of $796.9M in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending2¢$3.5M
  • Share buybacks98¢$216.4M

Out of $167.9M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.6

Financial statements

Revenue9101112136$796.9M in 2025+219% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $249.5M$249.5M20182019: $388.2M$388.2M2019+56%2020: $550.7M$550.7M2020+42%2021: $745.4M$745.4M2021+35%2022: $766.6M$766.6M2022+3%2023: $750.3M$750.3M2023−2%2024: $792.3M$792.3M2024+6%2025: $796.9M$796.9M2025+1%
Operating income9101112136$87.5M in 2025+13% since 2018
-$400.0M-$200.0M0$200.0M2018: $77.3M$77.3M20182019: $139.7M$139.7M2019+81%2020: -$275.7M-$275.7M20202021: $13.4M$13.4M20212022: $1.7M$1.7M2022−87%2023: -$27.0M-$27.0M20232024: $65.8M$65.8M20242025: $87.5M$87.5M2025+33%
Net income9101112136$30.4M in 2025−30% since 2018
-$300.0M-$200.0M-$100.0M0$100.0M2018: $43.8M$43.8M20182019: $66.0M$66.0M2019+51%2020: -$293.6M-$293.6M20202021: -$25.3M-$25.3M2021−91%2022: -$32.8M-$32.8M2022+30%2023: -$8.9M-$8.9M2023−73%2024: $16.4M$16.4M20242025: $30.4M$30.4M2025+86%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Revenue$796.9M$792.3M$750.3M
Cost of revenue, exclusive of depreciation and amortization presented separately below$57.6M$48.2M$66.9M
Product development and technology$121.0M$123.7M$135.8M
Sales and marketing$331.6M$367.1M$341.3M
General and administrative$114.0M$117.9M$125.5M
Depreciation and amortization$85.2M$69.5M$107.7M
Total costs and operating expenses$709.4M$726.5M$777.3M
Operating income (loss)$87.5M$65.8M-$27.0M
Other income (expense)$718.0K-$2.7M-$4.0M
Loss on extinguishment of debt$0-$2.1M$0
Interest income$10.9M$23.3M$32.2M
Interest expense-$42.6M-$52.9M-$56.7M
Total other expense, net-$31.0M-$34.4M-$28.6M
Income (loss) before income taxes$56.5M$31.5M-$55.6M
Income tax (expense) benefit-$26.1M-$15.1M$46.7M
Net income (loss)$30.4M$16.4M-$8.9M
Basic (in usd per share)$0.09$0.04-$0.02
Diluted (in usd per share)$0.09$0.04-$0.02
Basic (in shares)356.3M shares385.7M shares410.3M shares
Diluted (in shares)357.0M shares392.2M shares410.3M shares

Compare GoodRx with another company

The story

Financial performance

GoodRx was founded in Santa Monica, California in 2011. GoodRx experienced substantial growth in net income in 2017 ($9 million), 2018 ($44 million), and 2019 ($66 million), but recorded a loss of $293.6 million in 2020 due to IPO-related expenses.

In September 2020, GoodRx went public on the Nasdaq under the ticker symbol GDRX. The company priced its initial public offering at $33 per share, above the expected range of $24 to $28, raising more than $1.1 billion at an initial valuation of approximately $12.7 billion. In the first half of 2020, the company reported revenues of $257 million and net income of $55 million.

GoodRx generated $745.4 million in revenue for the full year 2021, a 35.36% increase over 2020. During the first half of 2021, the company's share price declined by 10.7%. The decline was attributed to increased competition in online pharmacy services and slower user growth.

GoodRx reported full-year revenue of $766.6 million, with adjusted EBITDA reaching $213.5 million, exceeding guidance in the fourth quarter. GoodRx reported that 41% of prescriptions filled using its coupons were newly adherent, meaning they would not have been filled without the service.

GoodRx reported a full-year 2023 revenue of $750.3 million, a decrease of 2.1% from 2022. However, its fourth-quarter revenue increased by 7% year-over-year. GoodRx achieved an Adjusted EBITDA of $217.4 million for the year and an Adjusted EBITDA Margin of 28.6%.

In 2024, GoodRx achieved 6% revenue growth with $792.3 million for the full year and turned a net loss into a positive net income of $16.4 million. The company also demonstrated strong operational efficiency, with a 32.8% increase in full-year Adjusted EBITDA.

In Q2 2025, GoodRx reported revenue of $203.1 million, a 1.2% increase from the previous year, and a net income of $12.8 million, a significant 92% jump, which resulted in a 6.3% net income margin. However, prescription transaction revenue declined by 3% due to a decrease in monthly active consumers, but this was offset by strong 32% growth in its Pharma Manufacturer Solutions business. GoodRx also saw a 7% decrease in subscription revenue.

Mergers and acquisitions

In 2019, GoodRx acquired HeyDoctor, a telemedicine company, to integrate virtual healthcare services into the platform.

Read the full text

In 2021, a health video content producer, HealthiNation was acquired by GoodRx, which helped provide consumers with health information and offered pharmaceutical manufacturers new ways to reach relevant audiences.

In April 2022, GoodRx acquired VitaCare Prescription Services from TherapeuticsMD to strengthen its pharma manufacturer solutions business.

Partnerships

In 2017, the company announced partnerships with major pharmaceutical companies to negotiate lowering prescription drug costs.

GoodRx has deep relationships with major pharmacy chains, including Walgreens, Walmart, CVS Caremark, and Publix, to allow customers to use GoodRx discounts and Gold benefits. GoodRx began its partnership with CVS Caremark in July 2023 to automatically apply coupons to insured CVS customers purchasing generic prescriptions at certain locations. In April 2024, GoodRx added Publix into its network, allowing GoodRx Gold members to use their cards at Publix Pharmacies.

GoodRx partners with Pharmacy Benefit Management like Caremark, Express Scripts, and MedImpact to apply their savings directly to eligible insurance plans and members.

GoodRx partners with companies like Affirm, Benefitfocus, and DoorDash to integrate their services that offer members discounts and financial flexibility for prescriptions.

GoodRx also partners with organizations like the American Academy of Family Physicians Foundation to support broader access to care.

In October 2022, GoodRx launched Provider Mode, which allows healthcare providers to use the app to compare costs of drugs for patients based on different payment methods and drug alternatives.

In 2025, GoodRx partnered with Novo Nordisk to offer discounted cash-pay access to semaglutide products like Ozempic and Wegovy through its platform and participating pharmacies.

From Wikipedia’s article on GoodRx, shared under CC BY-SA 4.0.8

Leadership

Who has led GoodRx, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (25)

Products and brands

  • GoodRx app

Listed on Wikidata.1

GoodRx started its telemedicine service GoodRx Care in September 2019. It lets people talk to a licensed provider online for common issues and get prescriptions even if they don't have insurance.

They also run condition-specific subscription plans that bundle online doctor visits, FDA-approved meds, and home delivery into one monthly payment.

On the weight management side, GoodRx offers prescriptions for GLP-1 drugs like semaglutide through their telemedicine platform. This got a boost when the oral version of Wegovy became widely available in the US in early 2026.

GoodRx works with drug makers like Novo Nordisk to make some medications (including semaglutide options) more affordable for people paying cash.

Read the full text

The telemedicine part took off after GoodRx bought HeyDoctor in 2019 and brought their virtual care tools into the main platform.

From Wikipedia’s article on GoodRx, shared under CC BY-SA 4.0.8

Timeline

  1. May 5, 2023New chief executive Scott Wagner becomes CEO18
  2. Sep 23, 2020Went public Listed on NASDAQ1
  3. Sep 23, 2020New chief executive Douglas Joseph Hirsch becomes CEO19
  4. Sep 23, 2020New chief executive Trevor Bezdek becomes CEO20
  5. Sep 2011Founded Founded1

Filings

416 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 68 major events, 233 insider forms, 51 large holders, 44 other. The latest 20:

  1. Oct 15, 20264 EDGAR
  2. Oct 15, 20264 EDGAR
  3. Oct 15, 20264 EDGAR
  4. Sep 15, 20264 EDGAR
  5. Sep 15, 20264 EDGAR
  6. Aug 26, 2026SCHEDULE 13D/A EDGAR
  7. Aug 26, 20264 EDGAR
  8. Aug 21, 20264 EDGAR
  9. Aug 19, 2026144 EDGAR
  10. Aug 17, 20264 EDGAR
  11. Aug 17, 20264 EDGAR
  12. Aug 12, 20264 EDGAR
  13. Aug 12, 20263 EDGAR
  14. Aug 5, 20268-K EDGAR
  15. Aug 5, 202610-Q EDGAR
  16. Aug 5, 20268-K EDGAR
  17. Jul 16, 20264 EDGAR
  18. Jul 16, 20264 EDGAR
  19. Jul 16, 20264 EDGAR
  20. Jun 18, 20268-K EDGAR

The 416 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

45 open-market trades by officers, directors and large owners since October 2021: 5 buys and 40 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2026FRANCISCO PARTNERS IV-A, L.P.10% ownerSale1,296,177$3.50$4.5MForm 4
Aug 25, 2026FRANCISCO PARTNERS IV-A, L.P.10% ownerSale127,273$3.44$437.8KForm 4
Aug 24, 2026FRANCISCO PARTNERS IV-A, L.P.10% ownerSale143,594$3.46$496.8KForm 4
Aug 21, 2026Francisco Partners GP IV Management Ltd10% ownerSale274,717$3.50$961.5KForm 4
Aug 20, 2026Francisco Partners GP IV Management Ltd10% ownerSale447,259$3.52$1.6MForm 4
Aug 19, 2026Francisco Partners GP IV Management Ltd10% ownerSale471,975$3.53$1.7MForm 4
Oct 15, 2025SEA VII Management, LLC10% ownerSale23,771$4.00$95.1KForm 4
Sep 5, 2025SEA VII Management, LLC10% ownerSale16,016$4.05$64.9KForm 4
Jul 3, 2025Spectrum VII Co-Investment Fund, L.P.10% ownerSale10,677$4.80$51.2KForm 4
Jun 6, 2025Spectrum Equity VII, L.P.10% ownerSale10,677$4.09$43.7KForm 4
Sep 3, 2024SEA VII Management, LLC10% ownerSale10,677$7.86$83.9KForm 4
Aug 12, 2024Nabiey RominChief Accounting OfficerSale79,000$6.77$534.8KForm 4
Nov 30, 2023Wagner ScottDirectorBuy21,652$5.76$124.7KForm 4
Nov 29, 2023Wagner ScottDirectorBuy26,348$5.90$155.5KForm 4
Nov 28, 2023Wagner ScottDirectorBuy4,157$6.00$24.9KForm 4
Nov 17, 2023Wagner ScottDirectorBuy26,664$5.26$140.3KForm 4
Nov 16, 2023Wagner ScottDirectorBuy104,079$5.16$537.0KForm 4
Jan 3, 2022Idea Men, LLCDirectorSale2,600$33.05$85.9KForm 4
Jan 3, 2022Slutsky AndrewPresident, ConsumerSale35,829$32.40$1.2MForm 4
Dec 28, 2021Voermann KarstenChief Financial OfficerSale12,500$33.05$413.1KForm 4

All 45 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Francisco Partners Management, LP60,078,184$173.0M47.9%No change
Ameriprise Financial Inc4,746,330$13.7M0.0%+290,570
Vanguard Capital Management LLC4,086,521$11.8M0.0%−174,995
Silver Lake Group, L.L.C.3,532,276$10.2M0.2%No change
Renaissance Technologies LLC3,245,738$9.3M0.0%−14,000
Vanguard Portfolio Management LLC3,208,264$9.2M0.0%−154,600
Petrus Trust Company, LTA3,098,559$8.9M0.8%No change
Dimensional Fund Advisors LP2,560,229$7.4M0.0%+109,088
Aqr Capital Management LLC2,326,080$6.7M0.0%+523,735
Jane Street Group, LLC2,313,184$6.7M0.0%+1,665,363
Prescott Group Capital Management, L.L.C.2,105,502$6.1M0.5%No change
BlackRock, Inc.1,857,708$5.4M0.0%−3,883
Technology Crossover Management X, Ltd.1,653,566$4.8M0.6%No change
Geode Capital Management, LLC1,171,369$3.4M0.0%+93,242
Northern Trust Corp904,290$2.6M0.0%+249,159
Stifel Financial Corp868,790$2.5M0.0%+151,391
Moore Capital Management, LP864,044$2.5M0.1%−665,371
Goldman Sachs Group Inc858,326$2.5M0.0%−199,635
Two Sigma Investments, LP742,181$2.1M0.0%+553,810
Nano Cap New Millennium Growth Fund L P740,000$2.1M1.6%No change
Universal- Beteiligungs- und Servicegesellschaft mbH738,833$2.1M0.0%+62,057
State Street Corp625,045$1.8M0.0%−386,144
Vanguard Fiduciary Trust Co587,886$1.7M0.0%+22,941
California State Teachers Retirement System584,872$1.7M0.0%+9,207
Charles Schwab Investment Management Inc553,844$1.6M0.0%−8,792

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 25, 2021Anthony E. Gonzalez, HouseBuy$100,001 - $250,000−188.4%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58